Last reviewed · How we verify

NCT04887324: HOPSCOTCH-II

Real-life Data of Constitutional Von Willebrand Disease in Western France

Completed Last updated 30 March 2025
What this trial tests

trial testing no intervention in Von Willebrand Diseases in 922 participants. Completed in 31 December 2024.

Timeline
7 July 2023
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorNantes University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment922
Start date7 July 2023
Primary completion31 December 2024
Estimated completion31 December 2024
Sites5 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Nantes University Hospital

Who can join

Eligibility, any sex, with Von Willebrand Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this observational study HOPSCOTcH-WILL II is to provide an accurate and detailed account of current Von Willebrand Disease (VWD) therapeutic management by collecting real-life data on hemorrhagic treated events in the 5 Western French Hemophilia Treatment Center. The HOPSCOTCH-WILL II study aims to describe therapeutic management of patients with VWD, following the provision of a recombinant drug in France; It will also permit to carry out a budget impact analysis to quantify the economic significance of this new era.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Von Willebrand Diseases

Currently open trials in the same condition.

Other Nantes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04887324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing